Luye Pharma Group Ltd. (HKG:2186)
Hong Kong
· Delayed Price · Currency is HKD 1.950
-0.040 (-2.01%)
May 9, 2025, 4:08 PM HKT
Luye Pharma Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 6,061 | 6,143 | 5,982 | 5,200 | 5,540 | Upgrade
|
| Revenue Growth (YoY) | -1.33% | 2.70% | 15.03% | -6.13% | -12.87% | Upgrade
|
| Cost of Revenue | 2,017 | 1,939 | 1,841 | 1,803 | 1,549 | Upgrade
|
| Gross Profit | 4,044 | 4,204 | 4,141 | 3,397 | 3,991 | Upgrade
|
| Selling, General & Admin | 2,398 | 2,700 | 2,403 | 2,276 | 2,185 | Upgrade
|
| Other Operating Expenses | 509.26 | 616.6 | 948.82 | 757.72 | 816.86 | Upgrade
|
| Operating Expenses | 2,908 | 3,317 | 3,351 | 3,033 | 3,002 | Upgrade
|
| Operating Income | 1,137 | 887.44 | 789.14 | 363.4 | 988.38 | Upgrade
|
| Interest Expense | -561.79 | -675.45 | -471.76 | -399.46 | -424 | Upgrade
|
| Interest & Investment Income | 157.19 | 209.97 | 176.1 | 189.69 | 151.05 | Upgrade
|
| Earnings From Equity Investments | -0.77 | 0.79 | 0.83 | 0.7 | 1.73 | Upgrade
|
| Currency Exchange Gain (Loss) | -71.73 | 46.03 | 106.2 | -24.09 | 49.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 182.5 | 241.77 | 109.08 | 129.65 | 202.4 | Upgrade
|
| EBT Excluding Unusual Items | 841.98 | 710.54 | 709.59 | 259.88 | 969.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.79 | 1.94 | 1.55 | -14.81 | -3.46 | Upgrade
|
| Gain (Loss) on Sale of Assets | 18.49 | 1.5 | -0.21 | 11.36 | 0.09 | Upgrade
|
| Legal Settlements | -14.65 | -14.52 | -14.07 | -273.48 | - | Upgrade
|
| Other Unusual Items | -8.39 | 0.63 | -27.09 | -57.51 | -23.76 | Upgrade
|
| Pretax Income | 839.22 | 700.1 | 669.76 | -74.56 | 942.17 | Upgrade
|
| Income Tax Expense | 194.21 | 161.02 | 86.47 | 70.23 | 238.91 | Upgrade
|
| Earnings From Continuing Operations | 645.01 | 539.08 | 583.3 | -144.78 | 703.27 | Upgrade
|
| Minority Interest in Earnings | -173.12 | -6.47 | 21.51 | 10.39 | 3.32 | Upgrade
|
| Net Income | 471.89 | 532.61 | 604.81 | -134.39 | 706.59 | Upgrade
|
| Net Income to Common | 471.89 | 532.61 | 604.81 | -134.39 | 706.59 | Upgrade
|
| Net Income Growth | -11.40% | -11.94% | - | - | -49.39% | Upgrade
|
| Shares Outstanding (Basic) | 3,762 | 3,728 | 3,481 | 3,445 | 3,187 | Upgrade
|
| Shares Outstanding (Diluted) | 3,762 | 3,728 | 3,481 | 3,445 | 3,194 | Upgrade
|
| Shares Change (YoY) | 0.89% | 7.11% | 1.03% | 7.87% | -0.85% | Upgrade
|
| EPS (Basic) | 0.13 | 0.14 | 0.17 | -0.04 | 0.22 | Upgrade
|
| EPS (Diluted) | 0.13 | 0.14 | 0.17 | -0.04 | 0.22 | Upgrade
|
| EPS Growth | -12.22% | -17.78% | - | - | -48.96% | Upgrade
|
| Free Cash Flow | -426.31 | 962.83 | 998.11 | -373.83 | 340.64 | Upgrade
|
| Free Cash Flow Per Share | -0.11 | 0.26 | 0.29 | -0.11 | 0.11 | Upgrade
|
| Gross Margin | 66.72% | 68.44% | 69.22% | 65.32% | 72.04% | Upgrade
|
| Operating Margin | 18.75% | 14.45% | 13.19% | 6.99% | 17.84% | Upgrade
|
| Profit Margin | 7.79% | 8.67% | 10.11% | -2.58% | 12.75% | Upgrade
|
| Free Cash Flow Margin | -7.03% | 15.67% | 16.69% | -7.19% | 6.15% | Upgrade
|
| EBITDA | 1,892 | 1,553 | 1,426 | 906.88 | 1,467 | Upgrade
|
| EBITDA Margin | 31.21% | 25.28% | 23.83% | 17.44% | 26.48% | Upgrade
|
| D&A For EBITDA | 755 | 665.47 | 636.47 | 543.48 | 478.79 | Upgrade
|
| EBIT | 1,137 | 887.44 | 789.14 | 363.4 | 988.38 | Upgrade
|
| EBIT Margin | 18.75% | 14.45% | 13.19% | 6.99% | 17.84% | Upgrade
|
| Effective Tax Rate | 23.14% | 23.00% | 12.91% | - | 25.36% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.